Drugs / UCB-MNCs
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT07175207 | Oct 2025 → Oct 2026 expected | enteritis, radiation-induced disorder | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07177456 | Oct 2025 → Oct 2026 expected | radiation-induced disorder | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03779711 | Jun 2019 → May 2022 overdue | hypoplastic left heart syndrome | Timothy J Nelson, MD, PhD | Active not recruiting | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UCB-MNCs | “BACKGROUND: Preliminary phase I clinical trial results revealed that autologous umbilical cord blood-derived mononuclear cells (UCB-MNCs) preserved right ventricular cardiac function.” PMID 40312733 ↗ May 2025 |
| Known as | umbilical cord blood mononuclear cells | “the umbilical cord blood mononuclear cells (UCB-MNCs) therapy” NCT07175207 ↗ |
| Modality | Cell therapy | “Researchers want to see if there are changes in the heart's structure/function following this stem cell-based therapy and compared to children that have not had cell-based therapy.” NCT03779711 ↗ |
| Route | Other | “The investigational product will be delivered into the right myocardium via sub-epicardial injections” NCT03779711 ↗ |